2023. Pembrolizumab Plus Trastuzumab and Chemotherapy for HER2-Positive Gastric or Gastro-oesophageal Junction Adenocarcinoma. Molecular Medicine Communications. 3, 02 (Dec. 2023), 89–92. DOI:https://doi.org/10.55627/mmc.003.02.0461.